FDA approved atezolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage 2 to 3A non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells.

[…] a mutation in the EGFR gene or the ALK gene. In adults whose cancer has gotten worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the EGFR gene or ALK gene, atezolizumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.

[…] Patients with NSCLC and SBM age 65 years or older at diagnosis from 2010 to 2019 SEER-Medicare database and received US Food and Drug Administration–approved ICIs (pembrolizumab/nivolumab/ipilimumab/ atezolizumab/durvalumab/cemiplimab) and/or chemotherapy (platinum-based doublets/taxane/pemetrexed/gemcitabine) as first-line systemic treatment were included, excluding those with no cranial radiation or ever being treated with targeted therapies. Overall survival time […]

[…] the first-line treatment for extensive-stage small cell lung cancer. Immunotherapies can prolong the body’s response to conventional chemotherapy and offers a promising addition to SCLC treatment. The immunotherapy drugs atezolizumab and durvalumab block the protein PD-L1 and boost the body’s immune response to cancer cells. When used in combination with chemotherapy, these drugs increased overall survival […]

[…] patients with ES-SCLC. Combined, these studies randomly assigned 245 patients to receive either an IV infusion of trilaciclib or a placebo before chemotherapy regimens containing carboplatin/etoposide (+/- atezolizumab) and topotecan. Approximately 90% of all patients with ES-SCLC will receive at least one of these regimens during the course of their treatment. The studies compared […]